Foghorn Therapeutics Inc. – Material Contracts Watch

EX-10.1

from 8-K 13 pages Material contract

12/34/56

EX-10.2

from 8-K 12 pages Material contract

12/34/56

EX-10.1

from 8-K 53 pages Material contract

12/34/56

EX-10.1

from 10-Q 11 pages July 18, 2024 Anna Rivkin 10 N. Main Street Stockton, Nj 08559 Dear Anna: This Letter Agreement (The “Agreement”) Sets Forth the Terms and Conditions of Your Employment With Foghorn Therapeutics Inc. (The “Company”). This Agreement Will Be Effective as of July 18, 2024. 1. Position and Duties

12/34/56

EX-10.1

from 8-K 11 pages April 12, 2024 Kristian F. Humer 155 West 11th Street #4g New York, Ny 10011 Dear Kristian: This Letter Agreement (The “Agreement”) Sets Forth the Terms and Conditions of Your Employment With Foghorn Therapeutics Inc. (The “Company”). This Agreement Will Be Effective as of April 16, 2024. 1. Position and Duties

12/34/56

EX-10.25

from 10-K 7 pages Consulting Agreement

12/34/56

EX-10.1

from 10-Q 11 pages August 4, 2023 Alfonso Quintás Cardama, M.D. 36 Pine Crest Road Newton Centre, Ma 02459 Dear Alfonso: This Letter Agreement (The “Agreement”) Sets Forth the Terms and Conditions Ofyour Employment With Foghorn Therapeutics Inc. (The “Company”). This Agreement Will Be Effective as of August 7, 2023. 1. Position and Duties

12/34/56

EX-10.2

from 10-Q 6 pages Promoted Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement

12/34/56

EX-10.1

from 10-Q 10 pages This Letter Agreement (This “Agreement”) Amends and Restates the Offer Letter Dated October 14, 2020 (The “Offer Letter”) by and Between You and Foghorn Therapeutics Inc. (The “Company”). This Agreement Sets Forth the Terms and Conditions of Your Continued Employment With the Company. This Agreement Will Be Effective as of August 1, 2022 (The “Effective Date”). 1. Position and Duties

12/34/56

EX-10.1

from 10-Q 3 pages First Amendment to Lease

12/34/56

EX-10.27

from 10-K 7 pages Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement

12/34/56

EX-10.26

from 10-K 10 pages January 10, 2022 This Letter Agreement (This “Agreement”) Confirms the Terms of the Remainder of Your Employment With Foghorn Therapeutics Inc. (Together With Its Subsidiary, the “Company”) and Certain Benefits to Be Provided to You by the Company. We Agree as Follows: Transition Period

12/34/56

EX-10.25

from 10-K 9 pages This Letter Agreement (The “Agreement”) Amends and Restates the Offer Letter Dated September 11, 2020 (The “Offer Letter”) by and Among You and Foghorn Therapeutics Inc. (The “Company”). This Agreement Sets Forth the Terms and Conditions of Your Employment With the Company. This Agreement Will Be Effective as of the Date on Which the Company Becomes Subject to the Reporting Obligations of Section 12 of the Securities Exchange Act of 1934, as Amended. Should This Not Occur for Any Reason, This Agreement Shall Be Void and of No Force or Effect. 1. Position and Duties

12/34/56

EX-10.24

from 10-K 10 pages October 14, 2020 (The “Offer Letter”) by and Among You and Foghorn Therapeutics Inc. (The “Company”). This Agreement Sets Forth the Terms and Conditions of Your Continued Employment With the Company. This Agreement Will Be Effective as of the Date on Which the Company Becomes Subject to the Reporting Obligations of Section 12 of the Securities Exchange Act of 1934, as Amended. Should This Not Occur for Any Reason, This Agreement Shall Be Void and of No Force or Effect. 1. Position and Duties

12/34/56

EX-10.23

from 10-K 10 pages April 27, 2016 (The “Offer Letter”) by and Among You and Foghorn Therapeutics Inc. (The “Company”). This Agreement Sets Forth the Terms and Conditions of Your Continued Employment With the Company. This Agreement Will Be Effective as of the Date on Which the Company Becomes Subject to the Reporting Obligations of Section 12 of the Securities Exchange Act of 1934, as Amended. Should This Not Occur for Any Reason, This Agreement Shall Be Void and of No Force or Effect. 1. Position and Duties

12/34/56

EX-10.22

from 10-K 11 pages October 14, 2020 Allan Reine by Email Delivery Dear Allan: Execution Version This Letter Agreement (The “Agreement”) Amends and Restates the Offer Letter Dated

12/34/56

EX-10.21

from 10-K 101 pages Collaboration Agreement Between Eli Lilly and Company and Foghorn Therapeutics Inc

12/34/56

EX-10.1

from 8-K 34 pages Stock Purchase Agreement

12/34/56

EX-10.1

from 10-Q 8 pages Consulting Agreement

12/34/56

EX-10.18

from 10-K 5 pages Reference Is Made to That Certain Letter Agreement Dated October 1, 2015, by and Between You and Foghorn Therapeutics Inc. (The “Company”), as Amended by That Certain Fee Increase Letter Dated January 22, 2019 (Such Agreement, as So Amended, the “Consulting Agreement”). the Purpose of This Letter (This “Amendment”) Is to Amend Certain Terms of the Consulting Agreement, as Described Below. A. Term of Consulting Agreement Section 6(a) of the Consulting Agreement Is Hereby Amended and Replaced in Its Entirety as Follows

12/34/56